{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:19:45Z","timestamp":1789600785409,"version":"build-2803163510"},"reference-count":22,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n            <jats:title>Background &amp; objectives:<\/jats:title>\n            <jats:p>Japanese encephalitis (JE) caused by mosquito-borne Flavivirus is one of the leading causes of viral encephalitis in Asia. Control strategies include vector control and human vaccination. Due to lack of immunization programmes in endemic regions, there are still high mortality and morbidity. A live-attenuated SA 14-14-2 JE vaccine (LAJEV) has been licensed and used in Asian countries, including India. We report the assessment of immunogenicity and safety of the vaccine in adults during the first mass adult vaccination campaign carried out in Assam, India.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>One thousand and seventy five adults (aged \u226515 yr) who received LAJEV were monitored for adverse events following immunization for one year. The safety assessment of vaccinated population was evaluated till 28 days and at 6 and 12 months. Blood samples collected from the enrolled participants were tested by plaque reduction neutralization test (PRNT<jats:sub>50<\/jats:sub>) to assess the neutralizing antibody titres (NATs) before vaccination and 28 days, six and 12 months post-vaccination (PV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among the 1075 vaccinated individuals, four reported minor adverse effects from 30 min to 28 days PV. Based on the pre-vaccination NAT, the study participants were categorized as seronegative, moderately seropositive and strongly seropositive. Nearly 85.5 per cent of JE seronegative participants seroconverted by 28 days PV. The geometric mean titre (GMT) in all the three groups increased by 28 days and decreased by six and 12 months PV. Nearly 60 per cent of the moderately positive individuals exhibited four-fold rise in GMT, 28 days PV. Almost 95.5 per cent of the participants in the study population remained seroprotected at the end of 12 months PV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation &amp; conclusions:<\/jats:title>\n            <jats:p>This study on immunogenicity and safety of LAJEV in adults showed that a single dose of the live-attenuated vaccine was safe and induced protective immunity to both JE seronegative and naturally seropositive adults. Further study is required to find out long term protective efficacy of this vaccine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_712_15","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T13:56:29Z","timestamp":1493387789000},"page":"886-892","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Immunogenicity &amp; safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults"],"prefix":"10.25259","volume":"144","author":[{"given":"Siraj Ahmed","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeb","family":"Kakati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafulla","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvita","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmee","family":"Topno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santoshkumar M.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradyumna K.","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadish","family":"Mahanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan D.","family":"Gupte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-14-20241212","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4269\/ajtmh.1959.8.719","article-title":"Ecologic studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions","volume":"8","author":"Buescher","year":"1959","journal-title":"Am J Trop Med Hyg"},{"key":"R2-14-20241212","first-page":"171","article-title":"Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections","volume":"267","author":"Solomon","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"R3-14-20241212","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/nm1144","article-title":"Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses","volume":"10","author":"Mackenzie","year":"2004","journal-title":"Nat Med"},{"key":"R4-14-20241212","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02752458","article-title":"Japanese encephalitis in India","volume":"64","author":"Reuben","year":"1997","journal-title":"Indian J Pediatr"},{"key":"R5-14-20241212","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF02724120","article-title":"Japanese encephalitis in India: an overview","volume":"71","author":"Kabilan","year":"2004","journal-title":"Indian J Pediatr"},{"key":"R6-14-20241212","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcv.2011.06.001","article-title":"A comparison of clinical features of Japanese encephalitis virus infection in the adult and pediatric age group with acute encephalitis syndrome","volume":"52","author":"Borah","year":"2011","journal-title":"J Clin Virol"},{"key":"R8-14-20241212","first-page":"188","article-title":"Observations on safety and serological efficacy from a large-scale field trial of Japanese encephalitis vaccine","volume":"6","author":"Ma","year":"1993","journal-title":"Chin J Biol"},{"key":"R9-14-20241212","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2007.04.052","article-title":"Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization","volume":"25","author":"Tandan","year":"2007","journal-title":"Vaccine"},{"key":"R10-14-20241212","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4269\/ajtmh.12-0196","article-title":"Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal","volume":"88","author":"Upreti","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"R12-14-20241212","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"key":"R13-14-20241212","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"R14-14-20241212","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/INF.0000000000000276","article-title":"Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety","volume":"33","author":"Feroldi","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R17-14-20241212","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/2224-3151.207040","article-title":"A review of Japanese encephalitis in Uttar Pradesh, India","volume":"1","author":"Kumari","year":"2012","journal-title":"WHO South East Asia J Public Health"},{"key":"R18-14-20241212","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2222-1808(12)60078-4","article-title":"Increasing trend of Japanese encephalitis cases in West Bengal, India - A threat to paediatric population","volume":"2","author":"Taraphdar","year":"2012","journal-title":"Asian Pac J Trop Dis"},{"key":"R19-14-20241212","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/jiv023","article-title":"A Japanese encephalitis vaccine from India induces durable and cross-protective immunity against temporally and spatially wide-ranging global field strains","volume":"212","author":"Singh","year":"2015","journal-title":"J Infect Dis"},{"key":"R20-14-20241212","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.vaccine.2013.11.002","article-title":"Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants","volume":"32","author":"Victor","year":"2014","journal-title":"Vaccine"},{"key":"R21-14-20241212","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1016\/j.vaccine.2014.09.012","article-title":"Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product","volume":"32","author":"Zaman","year":"2014","journal-title":"Vaccine"},{"key":"R22-14-20241212","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3346\/jkms.2015.30.5.612","article-title":"The immunogenicity and safety of the live-attenuated SA 14-14-2 Japanese encephalitis vaccine given with a two-dose primary schedule in children","volume":"30","author":"Kwon","year":"2015","journal-title":"J Korean Med Sci"},{"key":"R24-14-20241212","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1086\/517323","article-title":"Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects","volume":"176","author":"Liu","year":"1997","journal-title":"J Infect Dis"},{"key":"R26-14-20241212","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1471-2334-11-344","article-title":"Encephalitis temporally associated with live attenuated Japanese encephalitis vaccine: four case reports","volume":"11","author":"Jia","year":"2011","journal-title":"BMC Infect Dis"},{"key":"R27-14-20241212","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.vaccine.2013.11.107","article-title":"Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012","volume":"32","author":"Liu","year":"2014","journal-title":"Vaccine"},{"key":"R28-14-20241212","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1988.39.214","article-title":"Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children","volume":"39","author":"Xin","year":"1988","journal-title":"Am J Trop Med Hyg"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201644060-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:01:31Z","timestamp":1751497291000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/immunogenicity-safety-of-a-single-dose-of-live-attenuated-japanese-encephalitis-vaccine-sa-14-14-2-in-adults\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_712_15","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}